Apogee Therapeutics, Inc. (APGE)
D
Pipeline Grade
Financial Position (from SEC Filings)
$451.8M
Cash & Equivalents
$55.6M
Quarterly Burn Rate
24 mo
Est. Cash Runway
$10,048M
Market Cap
Estimated from most recent SEC quarterly filing. View SEC filings
Drug Pipeline (0 Assets)
No drugs indexed yet. Pipeline data is populated from ClinicalTrials.gov and openFDA.
Upcoming Catalysts
| Date | Event | Drug |
|---|---|---|
| 2026-09-01 | Phase1 Readout | — |
| 2026-11-01 | Phase2 Readout | — |
| 2026-12-01 | Phase1 Readout | — |
Active Clinical Trials (4)
| NCT # | Title | Phase | Status | Enrollment |
|---|---|---|---|---|
| NCT07003425 | A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis | PHASE2 | Recruiting | 350 |
| NCT06395948 | A Study Evaluating APG777 in Atopic Dermatitis | PHASE2 | Active Not Recruiting | 470 |
| NCT07027527 | An Active Comparator Safety Study Evaluating the Combination of APG777 + APG990 in Moderate-to-Severe Atopic Dermatitis | PHASE1 | Active Not Recruiting | 86 |
| NCT06920901 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Immunogenicity of APG777 in Adults With Asthma | PHASE1 | Active Not Recruiting | 31 |
Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.